Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01695044 · ClinicalTrials.gov registry record · Phase 2

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Phase 2 study of Prostate Cancer, sponsored by Progenics Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
119
Enrollment target
20
Study locations

NCT01695044: Completed Phase 2 study of Prostate Cancer, sponsored by Progenics Pharmaceuticals.

NCT01695044 is a Phase 2 study of Prostate Cancer that has completed, run by Progenics Pharmaceuticals. The registered enrollment target is 119 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01695044, a Phase 2 study of Prostate Cancer, has completed, sponsored by Progenics Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
119 participants
Enrollment target
20
Study locations

Study Summary

PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two groups of subjects with metastatic castration-resistant prostate cancer (mCRPC). One group comprises subjects who must have received at least one taxane-containing chemotherapy regimen (e.g. docetaxel, cabazitaxel). The second group comprises subjects who are cytotoxic chemotherapy-naïve. Subjects who are cytotoxic chemotherapy-naïve must have received and progressed on-, be ineligible for, refused, have an intolerance to-, or not have access to Radium-223. Both groups of subjects must also have received and progressed on abiraterone acetate and/or enzalutamide. If a subject is unable to receive abiraterone acetate and/or enzalutamide, Sponsor approval is required for participation in the study. Subjects will receive up to eight doses of PSMA ADC approximately once every three weeks.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG PSMA ADC

Study Locations (20)

California

  • - Burbank
  • - Encinitas
  • - Los Angeles
  • - San Diego

Maryland

  • - Baltimore
  • - Baltimore
  • - Rockville

Connecticut

  • - New Haven
  • - Norwalk

Alabama

  • - Birmingham

Arizona

  • - Tucson

Colorado

  • - Denver

Florida

  • - Port Saint Lucie

Hawaii

  • - Honolulu

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2012-09
Est. Completion 2015-02
Phase Phase 2

Sponsor

Progenics Pharmaceuticals

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01695044

The ClinicalTrials.gov registry entry for NCT01695044 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Progenics Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which PSMA ADC is the first listed.

NCT01695044 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Maryland, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01695044 about?

NCT01695044 is a clinical study titled "A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)". PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two groups of subjects with metastatic castration-resistant prostate cancer (mCRPC). One group comprises subjects who must have...

What is the current status of trial NCT01695044?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2012-09. Estimated completion is 2015-02.

What conditions does trial NCT01695044 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01695044?

The interventions under investigation include: PSMA ADC (DRUG).

Who is sponsoring clinical trial NCT01695044?

This trial is sponsored by Progenics Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01695044 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.